Chronic respiratory symptoms, spirometry and knowledge of COPD among general population

Miravitlles, Marc; Roza, Cristian de la; Morera, Josep; Montemayor, Teodoro; Gobartt, Elena; Martín, Antonio; Álvarez-Sala, José Luis

doi:10.1016/j.rmed.2006.02.024

Cited by 94 publications

(77 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As mentioned earlier, the cumulative 30-year incidence of CB in current smokers is 42% (22). However, it should be noted that CB has been described in 4 to 22% of never smokers (15,22), suggesting that other risk factors may exist. Other potential risk factors include inhalational exposures to biomass fuels, dusts, and chemical fumes…”

Section: Epidemiologymentioning

confidence: 98%

“…Table 1 provides an overview of the prevalence of cough and sputum production in population-based studies. CB is seen in 3.4 to 22.0% of adults (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19). This wide range of prevalence estimates may be due to varying definitions of CB (i.e., chronic phlegm versus chronic cough and phlegm) as well as the possible inclusion of subjects with bronchiectasis, a syndrome also characterized by chronic cough and daily viscid sputum production that is associated with pathologic airway dilation and recurrent infection.…”

Section: Epidemiologymentioning

confidence: 99%

See 1 more Smart Citation

Chronic Bronchitis and Chronic Obstructive Pulmonary Disease

Kim

Criner

2013

Am J Respir Crit Care Med

388

276

View full text Add to dashboard Cite

Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD). It has numerous clinical consequences, including an accelerated decline in lung function, greater risk of the development of airflow obstruction in smokers, a predisposition to lower respiratory tract infection, higher exacerbation frequency, and worse overall mortality. CB is caused by overproduction and hypersecretion of mucus by goblet cells, which leads to worsening airflow obstruction by luminal obstruction of small airways, epithelial remodeling, and alteration of airway surface tension predisposing to collapse. Despite its clinical sequelae, little is known about the pathophysiology of CB and goblet cell hyperplasia in COPD, and treatment options are limited. In addition, it is becoming increasingly apparent that in the classic COPD spectrum, with emphysema on one end and CB on the other, most patients lie somewhere in the middle. It is known now that many patients with severe emphysema can develop CB, and small airway pathology has been linked to worse clinical outcomes, such as increased mortality and lesser improvement in lung function after lung volume reduction surgery. However, in recent years, a greater understanding of the importance of CB as a phenotype to identify patients with a beneficial response to therapy has been described. Herein we review the epidemiology of CB, the evidence behind its clinical consequences, the current understanding of the pathophysiology of goblet cell hyperplasia in COPD, and current therapies for CB.Keywords: chronic obstructive pulmonary disease; chronic bronchitis; goblet cell hyperplasia; N-acetylcysteine; roflumilast Chronic obstructive pulmonary disease (COPD) is a common disease characterized by irreversible airflow obstruction and persistent inflammation to noxious environmental stimuli, usually cigarette smoke. It affects 12 to 16 million people in the United States and is the third leading cause of death and disease burden worldwide (1). COPD encompasses a spectrum of diseases, with chronic bronchitis (CB) at one end and emphysema at the other, with most individuals having some characteristics of both. The CB definition used in epidemiologic studies has been variable, but the classic definition is chronic cough and sputum production for at least 3 months per year for two consecutive years (2). CB has numerous clinical consequences, including an increased exacerbation rate, accelerated decline in lung function, worse health-related quality of life (HRQoL), and possibly increased mortality (3-6). We review the clinical phenotype of CB, the current understanding of its pathophysiology, and treatment options. EPIDEMIOLOGYCB is common in the general population. Table 1 provides an overview of the prevalence of cough and sputum production in population-based studies. CB is seen in 3.4 to 22.0% of adults (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19). This wide range of prevalence estimates may be due to varying definitions of CB (i.e., chronic phlegm ver...

show abstract

Section: Epidemiologymentioning

confidence: 98%

Section: Epidemiologymentioning

confidence: 99%

Chronic Bronchitis and Chronic Obstructive Pulmonary Disease

Kim

Criner

2013

Am J Respir Crit Care Med

388

276

View full text Add to dashboard Cite

show abstract

“…Siguiendo los componentes del Modelo de Autorregulación de Sentido Común (Leventhal et al, 1980), respecto a la identidad, se aprecia una falta de conocimiento sobre el nombre y síntomas de la enfermedad, constatado en otros estudios (Miravitlles et al, 2006) y supone no sólo un problema de denominación, sino también de conciencia y asignación de entidad a la enfermedad como tal, con caracterís-ticas propias, separada de otras enfermedades y diferenciada del efecto del envejecimiento.…”

Section: Discussionunclassified

“…Su prevalencia entre los 40 y 80 años en nuestro país se sitúa en torno a 10.2% (Miravitlles et al, 2009) siendo muy importante el infradiagnóstico de esta enfermedad (Miravitlles et al, 2006).…”

Section: Introductionunclassified

Cómo vivir con EPOC: percepción de los pacientes.

Muñoz-Cobos

Guasch²,

Cuenca-del-Moral

et al. 2015

AN PSICOL-SPAIN

View full text Add to dashboard Cite

The aim of this study is to determine the mental model that patients with COPD (chronic obstructive pulmonary disease<strong>)</strong>have about their illness analyzed by the Leventhal´s Common Sense of Self-Regulation Model. An exploratory-descriptive study using qualitative methodology was performed. We included COPD-diagnosed patients attending three urban and a rural primary care centres. We used video-taped group interviews and transcribed them using Atlas.Ti 5.2 program. 22 group interviews (2009 - 2011) and 58 patients were included. There were 3 additional sessions to final inform validation. The results show that patients did not have a defined mental model about COPD: this disease was insufficiently recognized; diagnosis was made in exacerbations and it was confused with other diseases; the cause of illness was related to tobacco consumption and to “something else”: fumes, colds and hard work. Patients tended to minimize their symptoms and limitations. Participants had wrong beliefs about colds, smoking only a few cigarettes effects and damage of inhaled treatment. Emotions as despair, resignation and fear were reported. We conclude that COPD patients showed confusion about many aspects of the disease (causes, symptoms, treatments). It was difficult to identify a mental model of the disease among COPD patients. <p> </p>

show abstract

“…Bu nedenle de bu hastalıklar yeterince teşhis ve tedavi edilememekte ve koruyucu önlemler yeterince uygulanamamaktadır. Sonuç olarak da bu hastalıklar morbidite ve mortalitenin en önemli nedenleri arasında yer almakta ve çok ciddi toplumsal ve ekonomik yük oluşturmaktadır (1)(2)(3). Dünya Sağlık Örgütü (DSÖ), kronik hastalıkların önlenmesi ve kontrolü için acil eylem çağrısında bulunmuş ve bu amaçla kronik solunum hastalıkları-na karşı küresel birlik "Global Alliance Against Chronic Respiratory Diseases (GARD)" kurulmuştur.…”

Section: Introductionunclassified